Search

Selected EMA news

Most of EHA’s regulatory activities focus on collaboration with the European Medicines Agency (EMA).

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

Faculty Information

We are honored that you have agreed to be part of the faculty for the EHA-SfPM Precision Medicine Meeting, to be held on September 25-27, 2024 in Copenhagen, Denmark

On this page, you will find the important deadlines as well as…

Read more

What to expect

FacultyThe faculty is made up of international leaders in clinical hematology research, statisticians, experts in regulatory and ethical aspects of clinical research and more.

Read more

CME-European Accreditors: A New European CME/CPD Association

A new association of accrediting boards in Continuing Medical Education/Continuing Professional Development in Europe has been established.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more

Faculty Information

We are honored that you have agreed to be a part of the faculty for the EHA-GBMTA-AHA Hematology Tutorial on New Aspects in Diagnostic Choices and Treatment Options of Hematological Malignancies, scheduled to be held on October 18-20, 2024 in Tbilisi, Georgia.…

Read more